Price T Rowe Associates Inc Repare Therapeutics Inc. Transaction History

Price T Rowe Associates Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$8.63 - $12.53 $85,635 - $124,335	-9,923 Reduced 36.9%	16,971 $180,000
Q4 2022 Feb 14, 2023	BUY	$12.5 - $18.13 $107,087 - $155,319	8,567 Added 46.75%	26,894 $396,000
Q3 2022 Nov 14, 2022	SELL	$11.57 - $15.59 $22.2 Million - $29.9 Million	-1,917,113 Reduced 99.05%	18,327 $223,000
Q2 2022 Aug 15, 2022	SELL	$8.45 - $14.84 $1.29 Million - $2.27 Million	-152,905 Reduced 7.32%	1,935,440 $27.1 Million
Q1 2022 May 16, 2022	SELL	$11.38 - $21.88 $893,068 - $1.72 Million	-78,477 Reduced 3.62%	2,088,345 $29.7 Million
Q4 2021 Feb 14, 2022	BUY	$19.66 - $28.11 $4.93 Million - $7.05 Million	250,849 Added 13.09%	2,166,822 $45.7 Million
Q3 2021 Nov 15, 2021	BUY	$25.71 - $35.24 $19 Million - $26.1 Million	739,969 Added 62.92%	1,915,973 $50.3 Million
Q2 2021 Aug 16, 2021	BUY	$30.1 - $34.85 $33.7 Million - $39.1 Million	1,121,157 Added 2044.15%	1,176,004 $36.7 Million
Q1 2021 May 17, 2021	BUY	$25.89 - $44.46 $983,664 - $1.69 Million	37,994 Added 225.44%	54,847 $1.68 Million
Q4 2020 Feb 16, 2021	BUY	$23.42 - $39.5 $394,697 - $665,693	16,853 New	16,853 $578,000

35.4M

50K

300

Ticker RPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,937,800
Market Cap $55.4M
Description
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that foc...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.